1-20 of 30
Sriram Balasubramanian
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing

Prasath Pararajalingam, Krysta M. Coyle, Sarah E. Arthur, Nicole Thomas, Miguel Alcaide, Barbara Meissner, Merrill Boyle, Quratulain Qureshi, Bruno M. Grande, Christopher Rushton, Graham W. Slack, Andrew J. Mungall, Constantine S. Tam, Rishu Agarwal, Sarah-Jane Dawson, Georg Lenz, Sriram Balasubramanian, Randy D. Gascoyne, Christian Steidl, Joseph Connors, Diego Villa, Timothy E. Audas, Marco A. Marra, Nathalie A. Johnson, David W. Scott, Ryan D. Morin
Journal: Blood
Blood (2020) 136 (5): 572–584.
https://doi.org/10.1182/blood.2019002385
Published: 2020
Includes: Supplemental data
Journal Articles

Clinical Impact of Ibrutinib with R-CHOP in Untreated Non-GCB DLBCL Co-Expressing BCL2 and MYC Genes in the Phase 3 Phoenix Trial

Peter Johnson, MDFRCP, Sriram Balasubramanian, Brendan Hodkinson, Michael Schaffer, Lori Parisi, S. Martin Shreeve, Steven Sun, Jessica Vermeulen, Laurie H Sehn, MD, Louis Staudt, Anas Younes, MD, Wyndham Wilson, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 354.
https://doi.org/10.1182/blood-2019-124443
Published: 2019
Journal Articles

Identification of a Genetic Signature Enriching for Response to Ibrutinib in Relapsed/Refractory Follicular Lymphoma in the Dawn Phase 2 Trial

Sriram Balasubramanian, Brendan Hodkinson, Stephen J. Schuster, MD, Nathan H. Fowler, MD, Judith Trotman, Georg Hess, Bruce Cheson, MD, Michael Schaffer, PhD, Shean-Sheng Wang, Sanjay Deshpande, Jessica Vermeulen, Gilles Salles, MD PhD, Ajay K. Gopal, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4147.
https://doi.org/10.1182/blood-2018-99-116472
Published: 2018
Journal Articles

JNJ-64457107, a CD40 Agonist, Induces Cell Death in BCL6 hi IRF4 neg GCB Subtype of DLBCL

Joshua J. Rusbuldt, MA, Andressa A. Smith, PhD, Sriram Balasubramanian, Gary Borzillo, PhD, Amy J. Johnson, PhD, Diana Alvarez Arias, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1674.
https://doi.org/10.1182/blood-2018-99-114622
Published: 2018
Journal Articles

Safety and Efficacy of the Combination of Ibrutinib and Nivolumab in Patients with Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia

Anas Younes, MD, Joshua Brody, MD, Cecilia Carpio, MD, Armando Lopez-Guillermo, Dina Ben-Yehuda, MD, A. Burhan Ferhanoglu, MD, Arnon Nagler, MD, Muhit Ozcan, MD, Irit Avivi, MD, Francesc Bosch Albareda, MD PhD, María Dolores Caballero Barrigón, MD PhD, Aisha Masood, MD, Michael Streit, MD MBA, John Alvarez, MD PhD, Rob Ceulemans, MS, Behzad Kharabi Masouleh, MD, Sriram Balasubramanian, PhD, Michael Schaffer, PhD, Shean-Sheng Wang, PhD, Nele Fourneau, MD, Wojciech Jurczak, PhDMD
Journal: Blood
Blood (2017) 130 (Supplement 1): 833.
https://doi.org/10.1182/blood.V130.Suppl_1.833.833
Published: 2017
Journal Articles

Combinatorial Treatment of Chronic Lymphocytic Leukemia with Ibrutinib and Venetoclax Is Superior to Treatment with Single Agents in the TCL1 Mouse Model

Erik Slinger, PhD, Sriram Balasubramanian, PhD, Joel D. Leverson, PhD, Eric Eldering, Arnon P. Kater, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3018.
https://doi.org/10.1182/blood.V130.Suppl_1.3018.3018
Published: 2017
Journal Articles

Ibrutinib inhibits pre-BCR + B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK

Ekaterina Kim, Christian Hurtz, Stefan Koehrer, Zhiqiang Wang, Sriram Balasubramanian, Betty Y. Chang, Markus Müschen, R. Eric Davis, Jan A. Burger
Journal: Blood
Blood (2017) 129 (9): 1155–1165.
https://doi.org/10.1182/blood-2016-06-722900
Published: 2017
Includes: Supplemental data
Journal Articles

Pseudo-Progression Among Patients with Follicular Lymphoma Treated with Ibrutinib in the Phase 2 DAWN Study

Gilles A. Salles, Judith Trotman, MB ChB, Michael Lill, MD BS, Bruce Cheson, MD, Stephen J. Schuster, MD, Jing-Zhou Hou, John A Radford, MB ChB, MRCP, MD FRCP, Andrew Spencer, Michael Schaffer, PhD, Rajendra Damle, PhD, Gary J. Gartenberg, MD, Jessica Vermeulen, MD PhD, Sriram Balasubramanian, PhD, Sanjay Deshpande, MD, Dolores Caballero, MD PhD
Journal: Blood
Blood (2016) 128 (22): 2980.
https://doi.org/10.1182/blood.V128.22.2980.2980
Published: 2016
Journal Articles

Ibrutinib As Treatment for Chemoimmunotherapy-Resistant Patients with Follicular Lymphoma: First Results from the Open-Label, Multicenter, Phase 2 DAWN Study

Ajay K. Gopal, MD, Stephen J. Schuster, MD, Nathan Fowler, MD, Judith Trotman, MBChB, Georg Hess, MD, Jing-Zhou Hou, Abdulraheem Yacoub, MD, Michael Lill, MD BS, Peter Martin, MD, Umberto Vitolo, MD, Wojciech Jurczak, MD, James Morton, MBBS, BSc(MD, FRACP, FRCPA, Dzhelil Osmanov, MD, Gary J. Gartenberg, MD, Jessica Vermeulen, MD PhD, Sriram Balasubramanian, PhD, Shean-sheng Wang, PhD, Sanjay Deshpande, MD, Gilles A. Salles
Journal: Blood
Blood (2016) 128 (22): 1217.
https://doi.org/10.1182/blood.V128.22.1217.1217
Published: 2016
Journal Articles

Early Changes in Circulating T-Cell Immune Profiles in Patients with Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Data from the Phase 3, Double-Blind HELIOS Trial

Rajendra Damle, PhD, Michael Schaffer, PhD, Shalini Chaturvedi, PhD, Charles Phelps, MSc, Regina Aquino, MSc, Michelle Mahler, MD, Mariya Salman, PhD, Angela Howes, PhD, Javier Loscertales, MD PhD, Marek Trneny, MD, Dina Ben Yehuda, MD, Alexander Pristupa, MD, Asher A. Chanan-Khan, MD, Sriram Balasubramanian, PhD
Journal: Blood
Blood (2016) 128 (22): 4397.
https://doi.org/10.1182/blood.V128.22.4397.4397
Published: 2016
Journal Articles

Mutation Impact of Targeted Genes in Diffuse Large B-Cell Lymphoma Patients Treated with Ibrutinib

Leo WK Cheung, Karl J. Schweighofer, Shiquan Wu, Hsu-Ping Kuo, Karl Eckert, Sriram Balasubramanian, PhD, Deborah Ricci, Yu Liang, Darrin Beaupre, Betty Y. Chang
Journal: Blood
Blood (2015) 126 (23): 2642.
https://doi.org/10.1182/blood.V126.23.2642.2642
Published: 2015
Journal Articles

Ibrutinib Vs Temsirolimus: Results from a Phase 3, International, Randomized, Open-Label, Multicenter Study in Patients with Previously Treated Mantle Cell Lymphoma (MCL)

Simon Rule, MD, Wojciech Jurczak, MD PhD, Mats Jerkeman, MD PhD, Rodrigo Santucci, MD, Chiara Rusconi, MD, Marek Trneny, MD, PhD, Prof., Fritz Offner, MD PhD, Dolores Caballero, MD, Cristina Joao, MD PhD MSc, Mathias Witzens-Harig, MD, Georg Hess, MD, Isabelle Bence-Bruckler, MD FRCPC, Seok-Goo Cho, MD, Sriram Balasubramanian, PhD, Nibedita Bandyopadhyay, PhD, Steven Sun, PhD, Jenna Goldberg, MD, John Bothos, PhD, Shana Traina, PhD, Christopher Enny, BS, Aleksandra Rizo, MD, Jessica Vermeulen, MD PhD, Martin H. Dreyling, MD PhD
Journal: Blood
Blood (2015) 126 (23): 469.
https://doi.org/10.1182/blood.V126.23.469.469
Published: 2015
Journal Articles

TP53 Mutations and Other Cell-Intrinsic Determinants of the Apoptotic Response to Ibrutinib in Chronic Lymphocytic Leukemia

Nisar A. Amin, Sriram Balasubramanian, PhD, Kamlai Saiya-Cork, Sami N. Malek
Journal: Blood
Blood (2015) 126 (23): 4165.
https://doi.org/10.1182/blood.V126.23.4165.4165
Published: 2015
Journal Articles

Impact of High Risk Prognostic Parameters and Addition of Ibrutinib to Bendamustine/Rituximab (BR) on Outcomes for Patients with Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) from the Phase 3 Double-Blind HELIOS Trial

Asher Chanan-Khan, MD, Paula Cramer, MD, Graeme Fraser, MDFRCPC, Rodrigo Santucci Silva, MD, Sebastian Grosicki, MD PhD, Aleksander Pristupa, MD, Marie Sarah Dilhuydy, MD, Andre Goy, MD, Anthony R. Mato, MD MSCE, Rajendra Damle, PhD, Charles Phelps, MS, Michelle Mahler, MD, Mariya Salman, PhD, Michael Schaffer, PhD, Angela Howes, PhD, Sriram Balasubramanian, PhD
Journal: Blood
Blood (2015) 126 (23): 1732.
https://doi.org/10.1182/blood.V126.23.1732.1732
Published: 2015
Journal Articles

Improvement of Quality of Response with Ibrutinib Plus Bendamustine/Rituximab Vs Placebo Plus Bendamustine/Rituximab for Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Paula Cramer, MD, Asher Chanan-Khan, MD, Graeme Fraser, MDFRCPC, Fatih Demirkan, MD, Rodrigo Santucci Silva, MD, Halyna Pylypenko, MD, Sebastian Grosicki, MD PhD, Ann Janssens, MD, Andre Goy, MD, Jiri Mayer, Prof., MD, Marie Sarah Dilhuydy, MD, Javier Loscertales, MD PhD, Nancy L. Bartlett, MD, Abraham Avigdor, MD, Simon Rule, MD, Steven Sun, PhD, Charles Phelps, MS, Michelle Mahler, MD, Mariya Salman, PhD, Michael Schaffer, PhD, Sriram Balasubramanian, PhD, Angela Howes, PhD, Michael Hallek, MD
Journal: Blood
Blood (2015) 126 (23): 2938.
https://doi.org/10.1182/blood.V126.23.2938.2938
Published: 2015
Journal Articles

Biomarker Analysis in a Phase Ib Study Combining Ibrutinib with R-CHOP in Patients with CD20-Positive B-Cell Non-Hodgkin Lymphoma (NHL)

Shalini Chaturvedi, Michael Schaffer, Cuc Davis, Regina Aquino, Emily Stepanchick, Yasuhiro Oki, Nele Fourneau, Anas Younes, Sriram Balasubramanian
Journal: Blood
Blood (2014) 124 (21): 2965.
https://doi.org/10.1182/blood.V124.21.2965.2965
Published: 2014
Journal Articles

Effects of Ibrutinib on Rituximab and GA-101 Induced Antibody-Dependent Cell Cytotoxicity (ADCC) in Lymphoma Cells in Vitro

Cuc Davis, Emily Stepanchick, Khaja Syed, Amy Axel, Brett Hall, Kate Sasser, Sriram Balasubramanian
Journal: Blood
Blood (2014) 124 (21): 3117.
https://doi.org/10.1182/blood.V124.21.3117.3117
Published: 2014
Journal Articles

Mutational Analysis of Patients with Primary Resistance to Single-Agent Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Sriram Balasubramanian, Michael Schaffer, William Deraedt, Cuc Davis, Emily Stepanchick, Regina Aquino, Zhilong Yuan, Britte Kranenburg, Irit Avivi, Martin Dreyling, Simon Rule, Michael Wang, MD, Sen Hong Zhuang, Aleksandra Rizo, Georg Lenz
Journal: Blood
Blood (2014) 124 (21): 78.
https://doi.org/10.1182/blood.V124.21.78.78
Published: 2014
Journal Articles

The Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), Has Preferential Activity in the ABC Subtype of Relapsed/Refractory De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results of a Multicenter, Open-Label, Phase 2 Study

Wyndham H. Wilson, MD, PhD, John F. Gerecitano, MD, PhD, Andre Goy, MD, Sven de Vos, MD, PhD, Vaishalee P. Kenkre, MD, Paul M. Barr, MD, Kristie A. Blum, MD, Andrei R. Shustov, MD, Ranjana H. Advani, MD, Jason Lih, PhD, Mickey Williams, PhD, Roland Schmitz, PhD, Yandan Yang, PhD, Stefania Pittaluga, MD, PhD, George Wright, PhD, Lori A. Kunkel, MD, Jesse McGreivy, MD, Sriram Balasubramanian, PhD, Mei Cheng, PhD, Davina Moussa, Joseph J. Buggy, PhD, Louis M. Staudt, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 686.
https://doi.org/10.1182/blood.V120.21.686.686
Published: 2012
Journal Articles

CBFβ-SMMHC Inactivates p53 Tumor Suppressor Through Aberrant Protein Interaction and Recruitment of HDAC8

Jing Qi, Sandeep Singh, Qi Cai, PhD, Hongjun Liu, Hieu Vu, Sriram Balasubramanian, Ya-Huei Kuo, PhD
Journal: Blood
Blood (2012) 120 (21): 772.
https://doi.org/10.1182/blood.V120.21.772.772
Published: 2012